The biopharma's shares tanked on bad news from its prostate cancer drug, but earlier data could turn that around.

The company halted the study of its prostate cancer drug after it caused a high number of deaths.

The biopharma company drops on halted study news, due to 100 deaths related to its prostate cancer drug.

Data on whether it causes cancer are set to be released next week.

If the Merck/Schering-Plough drug escapes worries about cancer, there is still the question of whether it works.

The health care manager reduced its guidance due to rising health care costs and poor economic conditions.

The struggling biopharma conducts a reverse-stock split to satisfy trading rules.

The health care services manager cut its outlook due to increased economic pressure.

The pain drug manufacturer continues to turn down the company's 'undervaluing' $1.4 billion offer.

Eli Lilly gets European approval for its chronic pain and depression drug to treat generalized anxiety disorder.

The pain-drug manufacturer reveals a bid for it competitor, whose board has already said "no thanks."

The medical device maker beats expectations as obstacles mount.

The health care provider pays for its accounting mistakes, but faces further fines.

The medical device maker beat expectations for the first fiscal quarter of 2009.

Despite losing some ground in the stent market, the medical device maker pushed through with a strong quarter.

Having already unloaded Symbion's vitamins and supplements unit, the Australian clinics operator decides to sell its pharmacy unit to a privately held Hong Kong firm, Zuellig Group.

U.S. issues a warning concerning the diabetes drug.

Shares of the small biotech jumped on positive results of its new inflammatory disease treatment.

Biotech's shares shoot up after positive results for treatment of rare inflammatory condition.

Why it's so hard to know if the diabetes drug Byetta causes a severe side effect.